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Cannabis as Medicine
• Cannabis (marijuana, hemp) is one of 
the oldest known psychoactive plants
• First reported use as medicine >3000 
years ago
• Introduced into Western Medicine in 
1840’s by Dr. W.B. O’Shaughnessy
• Promoted for putative analgesic, 
sedative, anti-inflammatory, 
antispasmodic and anticonvulsant 
properties
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Cannabis as Medicine
• Interest waned in early 1900’s with advent of opiates, 
barbiturates, chloral hydrate, aspirin and syringes
• First federal restrictions in 1937 with Marihuana Tax 
Act ($1/oz for medical use, $100/oz for recreational 
users)
• AMA virtually alone in opposing act
• Believed objective data re: harmful effects were lacking
• Act would impede future clinical investigations
− Removed from US Pharmacopoeia in 1942






• Other hallucinogenic amphetamine derivatives
• Methaqualone
• Illicit fentanyl derivatives
• Gamma hydroxybutyrate (GHB)
Controlled Substance Act 1970
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• Contains over 400 chemical compounds
• Highest concentration of bioactive compounds in resin exuded 
from flowers of female plants 
• Main psychoactive component believed to be delta-9-THC
• At least 70 other cannabinoids identified in pyrolysis products
• Delta-8-THC similar in potency but only in small concentration
Cannabis as Medicine
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• ∆9-tetrahydrocannabinol (THC) is the primary active ingredient of 
cannabis
• Secondary compounds may enhance the beneficial effects of THC
• Other cannabinoid and non-cannabinoid compounds may reduce 
THC-induced anxiety, anticholinergic effects and 
immunosuppression
• Terpenoids and flavonoids may increase cerebral blood flow, 
enhance cortical activity, kill respiratory pathogens and provide anti-
inflammatory activity
Non-THC Components of Cannabis
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• Lipid (oil) soluble
• AEA anandamide (AEA).  Binds to CB1 receptors.  CBD in cannabis 
inhibits its enzymatic clearance.
• Two-aclglycerol, aka two-arachidonyl glycerol (2 AG). Acts on both CB1 
and CB2 receptors.  CBD in cannabis stimulates its release.
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 CB1 receptors for AEA and 2AG endocannabinoids are particularly 
abundant in the central nervous system, also in adipose tissue, liver, 
lungs, uterus & placenta.
 Activation of CB1s in central and peripheral nerves can be analgesic. 
 CB1s on GABA interneurons which can disinhibit pain projection 
neurons.  
 Neuro-transmitters modulated include acetylcholine, norepinephrine, 
dopamine, 5-hydroxy-tryptamine, GABA and D-aspartate.      
Endocannabinoid Receptors
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Cannabis contains at least 68 
cannabinoids such as:
• THC – delta-9tetra-hydro-cannabinol
• CBD – cannabidiol
• CBN, CBG, CBC, THCV
Plus other bioactive components:
• Terpenes – the aromatic oils
• Flavonoids eg anti-inflammatory 
cannaflavins
Exo-Cannabinoids
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Δ9-THC
• delta-9-tetra-hydro-cannabinol
• Psychoactive “narcotic”– Sativa high, Indica stone
Alters mood, behavior, perception & consciousness.
• CB1 - Receptors primarily in the CNS but also in peripheral 
nervous system and other organs.
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• Stimulates release of endocannabinoid 2-AG which 
acts on CB1 and CB2 receptors. 
• Balances psychotropic effects of THC at CB1s in CNS, 
reducing disorientation, tachycardia, drowsiness.
• Abundant in Indica leaf & bud.
• Immuno-modulator, anti-inflammatory, analgesic, 
anxiolytic, lowers BP, anti-nausea, neuroprotective.
CBD - Cannabidiol
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CB1 receptors for AEA and 2AG 
endocannabinoids are particularly abundant 
in the central nervous system, also in adipose 
tissue, liver, lungs, uterus & placenta.
Activation of CB1s in central and peripheral 
nerves can be analgesic. 
CB1s on GABA interneurons which can 
disinhibit pain projection neurons.  
Neuro-transmitters modulated include 
acetylcholine, norepinephrine, dopamine, 5-
hydroxy-tryptamine, GABA and D-aspartate.      
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• CB2 receptors for 2AG / CBD are found in liver, spleen, GI 
tract, heart, bones, kidneys, and in the peripheral nervous 
system.
• Many are in immune tissues such as spleen, tonsils, 
lymphatics and leucocytes including in order of 
concentration:
B-cells, NK cells, 
Monos, PMNs, 
CD4 and CD8 T cells.   
CB2 Receptors
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Cannabinoids inhibit the TH1 immune response, with its pro-
inflammatory cytokines IL-1, IL-2, IL-12, IL-18, and IFN.   
These may inhibit auto-immune diseases including multiple 
sclerosis, IDDM1, RA, psoriasis  and Crohn’s.  
Stimulated by 2-AG and therefore by CBD.
Cannabinoids & Immune Function
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• Give the aroma and flavor to cannabis.
• D-limonene – see Boik 1998 – anti-mutagenic, immune 
modulator, anti-neoplastic. Gould 1997, Crowell 1999 
• Pinene, linalool, terpeneols, citronellol, myrcene, 
caryophyllene, pulegone, cineole, cymene.
• Sedative and anti-depressant effects.
• Lessen anxiety from other cannabis bio-actives
Terpenes
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• Topical, ingestible, suppository and vaporized  for nausea, appetite, 
cachexia or pain.
• Cannabis sativa  can be energizing.  
• Cannabis indica is more sedating may cause dizziness and impaired
memory.
• A balance in the ratio of CBD to THC can reduce intoxication
ie indica leaf extract or juice.
Cannabis effects
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Dry mouth, dehydration, reduced saliva and tears, reduced energy, 
weakness, light-headedness, dizziness, postural hypotension, syncope, 
immobility (“couch-lock“), mental clouding, confusion, dysphoria, 
lethargy, anxiety (often re: death or loss of control), impaired memory, 
amnesia, increased reaction time, reduced motor performance, 
decreased attention, reduced coordination, nausea, stomachache, 
colored stool or urine, conjunctival injection (bloodshot eyes), 
bronchitis, tachycardia.
Intoxication is aggravated by MSG!
Adverse Effects





• Allodynia, pain of inflammation
• Muscle spasticity 
Severe pain requires both THC and CBD.   
Abrams 2011    Martin-Sanchez 2003
Cannabinoid  Analgesia
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• Elevated levels of the CBI receptor – like the opioid – are 
found in areas of the brain that modulate nociceptive 
processing
• CB1 and CB2 agonists have peripheral analgesic actions
• CBs may also exert anti-inflammatory effects
• Analgesic effects not blocked by opioid antagonists
Cannabinoids and Pain
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• In mice and rats, THC greatly enhances analgesic effect 
of morphine in a synergistic fashion
• Increased potency of other mu opioids (hydromorphone 
and oxymorphone) seen with oral-∆-9-THC in mouse 
models
• Possibility of enhanced and persistent analgesic effect at 
lower opioid doses
Cannabinoid: Opioid Interactions
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• PTSD – Pruning memory, time distortion, altered perceptual 
state and disinheriting may be useful in moving trauma into long-
term memory – “just one of the things that happened in my life”.    
Rx 8+ mg 
• Cannabinoids can reduce opiate use and dependence, and may 
stand-in for alcohol and other psychoactive drugs.
• May ease anxiety (CBD), Tourrete’s, epilepsy, MS, agitated 
dementia.
• Caution: Sedative drugs interact strongly!
PTSD, opiates, neurological disorders
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• At age 13 a human child has well-developed pleasure/reward 
centres so can get high, but has not fully developed pre-frontal 
cortex until age 24.
• Cannabis primarily acts in the pre-frontal cortex of adults, who 
are able to use that area to create forethought of 
consequences of action and to control impulses. 
• Early exposure to cannabis may damage brain development 
and may increase risk of psychoses. 
Danger To Children
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Risk of dependency is about 9%, less than for tobacco, alcohol (15%), cocaine 
(17%) or heroin (23%).
The hallmarks of dependency are compulsion, craving, loss of control of 
intake,  continuing to use despite negative consequences in physical health or 
social, recreational or work activities or relationships, tolerance, persistent 
desire to reduce intake but inability to do so, and withdrawal reactions. 
N-acetyl-cysteine helps break dependence    Gray 2012
Dependence
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• Heavy users who suddenly withdraw may have mild irritability, 
anger, aggression, restlessness, agitation, sleep disorder, 
strange dreams, depression, hyperhidrosis, loss of appetite, 
weight loss, rebound intraocular pressure increase. 
• Withdrawal  symptoms tend to peak at day 2 to 4, and end by 
7 to 14 days. 
• THC will clear off in about 35 days, metabolites can be 
detected in urine for up to 80 days.
Drug Withdrawal
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• Anandamide in low concentrations in mice leads to a potent 
enhancement of appetite
• CBI receptors implicated in food intake control 
(hypothalamus and limbic system)
• CB1 knockout mice eat less than wild type litter mates
• CB1 receptors involved in motivational/reward aspects of 
eating
Cannabinoids and Appetite
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 Interest in 70’s prompted by anecdotal reports when 
available antiemetics were inadequate
 In randomized trials, oral THC better than placebo and 
equivalent or superior to prochlorperanzine
 Smoked THC appeared superior to oral
 THC <metoclopramide <5-HT₃ antagonists
Cannabis and Chemotherapy N & V
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2015 Cochran Review
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• 23 RCTS
• N&V decreased in those who received verum vs placebo
• Similar to conventional anti-nausea medicines. However, more 
people experienced side effects such as ’feeling high’, dizziness, 
sedation,  dysphoria and left the study due to the side effects 
with cannabis-based medicines, compared with either placebo or 
other anti-nausea medicines. 
• In trials where people received cannabis-based medicines and 
conventional medicines in turn, overall people preferred the 
cannabis-based medicines
Cochrane review conclusions
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Pain   9 RCTS 1975-2011.  9/9 positive benefit.  Dose dependent response
Appetite ad weight  5 RCTS 1986 -2007.  5/5 increased appetite and weight 
with dose dependence
Drug: herb interactions  none with taxanes or irinotecan
No evidence of lung cancer or COPD risk with smoking.
Medical Cannabis and cancer.  Joan Cramer, 
MD. CA Cancer J Clin 2015;65:109-122.
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• 1000 responses from randomly selected members of 
American Society of Clinical Oncology surveyed in 1990
− 44% had recommended marijuana to at least one patient
− Marijuana believed to be more effective than dronabinol by 
44%; dronabinol more effective by 13%
 Doblin et al JCO 1991
Oncologists’ THC Survey
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• In cancer trials, oral THC 20 mg was comparable to codeine 
120 mg but with marked psychological effects
• Cannabinoids also effective in rat model of neuropathic pain
THC and Analgesia
Third Annual Palliative Care Institute Conference
• HIV-related painful distal symmetric polyneuropathy is a 
common problem
• Current therapy for HIV neuropathy pain is inadequate
− Opioids generally ineffective
− Anticonvulsants in common use currently
− Anecdotal reports of marijuana’s efficacy
• Cannabinoids effective in preclinical models of neuropathic 
pain
Supported in part by UC CMCR and NIH GCRC Funds
Cannabis in HIV Neuropathy
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• Co-administration of vaporized cannabis with oral sustained release 
opioids is safe
• Co-administration of vaporized cannabis in subjects on stable doses of 
morphine or oxycodone appears to enhance analgesia
• Co-administration of vaporized cannabis trends towards lowering 
concentration of the opioids
− The PK effects would be expected to reduce the analgesic effects of 
the opioids
− The effect of vaporized cannabis to enhance opioid analgesia occurs by 
a pharmacodynamics, not a pharmacokinetic mechanism
Cannabis: Opioid Conclusions
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• The accumulated data indicate a potential therapeutic value for 
cannabinoid drugs
− Pain relief
− Control of nausea and vomiting
− Appetite stimulation
• THC therapeutic effects best established
• Effects of cannabinoids generally modest; usually there are more 
effective medications
IOM: Efficacy of Cannabinoid Drugs
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 Often described as a “side–effect” of Rx
 Is it really an “adverse experience” particularly in the 
terminal patient?
 Is a single treatment that increases appetite, decreases 
nausea and vomiting, relieves pain and improves mood and 
sleep a potentially useful tool in palliative medicine?
Cannabis-Induced Euphoria
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 No deaths have been reported from OD
 Estimate 800 cigarettes required to kill (death secondary 
to CO not cannabinoid poisoning)
 By comparison, 300 ml of vodka or 60 mg of nicotine 
would be lethal
 Addictive potential and minor withdrawal syndrome less 
than or equal to caffeine
The Safety of Cannabis
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The effect of cannabis on urge incontinence in patients 
with multiple sclerosis: a multicenter, randomized 
placebo-controlled trial
Freeman et al 2006
Cannabis and MS-related 
Incontinence
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• Increasing body of preclinical evidence suggests 
cannabinoids may have activity
• Anti-oxidant and anti-inflammatory effects
• Possibility of anti-tumor activity via cannabinoid receptors 
inducing apoptosis and impairing tumor vascularization
• Gliomas and skin tumors seem responsive in animal models
Cannabis as an Anti-Cancer Agent
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 Cannabinoid administration to nude mice curbs 
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• Cannabinoids induce apoptosis in gliomas
• Cannabinoids administration in mouse models differentiates tumor 
vascular hyperplasia
− Associated with reduced expression of VEGF and VEGF receptors
• Cannabinoids decrease the activity of matrix metalloproteinase-2; 
hence may also modify glioma invasiveness
− All of the above in mice with gliomas
Velasco Neuropharmacology 04
Cannabinoids and Cancer
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• In colorectal cancer cell lines, CBD
− Protected DNA from oxidative damage
− Increased endocannabinoid levels
− Reduced cell proliferation
• In mice treated with azoxymethane, CBD 1 mg/kg decreased 
aberrant crypt foci polyps and tumor formation
• At non-cytotoxic concentration, CBD anti-proliferative vs 
colorectal cancer cell lines
Aviello et al. J Moi Med 2011
Cannabidiol and Colon Cancer
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• Cannabinoids inhibit cancer gene 
expression of Id-1 protein involved 
in aggressive growth and metastasis 
of breast & ovarian cancer.  McAllister 2007
• Cannabinoids retard angiogenesis
Freimuth 2010
• Cannabinoids inhibit inflammation 
via TNFα Chianchi 2008
Cannabinoids for Cancer
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• directly retard cancer cell growth, eg CBD inhibits proliferation by 
antagonizing GPR55 receptors.      Kotsikorou2013
• selectively kill cancer cells, mutated cells 
• THC inhibits angiogenesis   Blazquez 2004
• THC inhibits cancer cell respiration even where there are no 
cannabinoid receptors. Ruiz 1999
• CBD + THC inhibit metastasis  Murase 2013
• CBD + THC reduce free radicals of oxygen.
Cannabinoids have anti-cancer 
activities
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• Cannabinoids inhibit the TH1 immune response, with its pro-
inflammatory cytokines IL-1, IL-2, IL-12, IL-18, TNFα and IFN.    
Borgelt 2013
• Modulate inflammatory growth factors 
• THC inhibits EGFR.     Blasquez 2004
• THC is anti-cachexic, THC + CBD are anti-nausea. 
• Terpenes such as D-limonene also have anti-tumor activity. 
Cannabis for Cancer 
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• Low (6-20%) and variable bioavailability
• Peak [Plasma] within 1-6 hr; may remain elevated for several 
hrs
• Initially oxidized in liver to 11-OH-THC, as potent psychoactive 
metabolite
• Further oxidation of 11-OH-THC leads to elimination products 
(urine and feces)
• Terminal half life 20-30 hrs
Oral THC Pharmacology
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• Rapidly absorbed into blood stream and redistributed
• Considerable amount of dose lost in smoke and destroyed by 
pyrolysis
• Peak blood levels achieved at end of smoking decline rapidly 
over 30 minutes
• Smoking achieves higher peak concentration but shorter 
duration of effect
• Smaller amts 11-OH-THC formed
Smoked THC Pharmacology
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• GW Pharmaceuticals, England
• ~ 50 : 50 mix of THC & CBD
• Whole plant extract – terpenes, flavonoids
• Oral spray – corrosive to gingiva
• Approved in Canada.  Expensive
• Rx for neuropathic pain and muscle spasticity
• Gets many patients too high
Johnson 2013
Sativex®
Third Annual Palliative Care Institute Conference
• THC pill – 2.5, 5 or 10 mg
• High blood levels of psychoactive 11-hydroxy-THC
• Expensive, less effective than cannabis Cooper 2013
..........................................................................
Nabilone®
• Synthetic THC from Cesamet, circa 2006
• For pain, chemo nausea, vomiting, loss of appetite
• 50% drop out: dizziness, sedation, dysphoria
• Most users prefer cannabis
Marinol® (dronabinol)
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• Multiple variables dictate that dosing be highly individualized
• A patient-determined self-dosing model is recommended
• Self titration model acceptable in view of the plant and host 
variables and the low toxicity of cannabis
• Gabapentin and example of another drug with relatively low 
toxicity and high dosing limits titrated to effect 
Carter et al IDrugs 2004
Cannabis Dose Guidelines
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• A joint = 0.5 to 0.8 grams of cannabis with about 4 to 8% THC
• About 20 to 70% of that ~ 5 mg of THC reaches the lungs.  
• 5 to 50% of the THC is bioavailable - into systemic circulation, 
• 31% of  CBD - cannabidiol reach systemic circulation,
• 38% of  CBN - cannabinoids reach systemic circulation. 
• Plasma peaks of THC occur in 3 to 10 minutes, often before finishing a joint.  
• The most psychoactive metabolite 11-hydroxy-THC reaches a peak in 13 minutes.   
• It rapidly moves into highly vascular tissues, then slowly distributes into fatty 
tissue.  
• Plasma clears in about 3 hours, and the high usually lasts about 1 to 2 hours, 
sometimes up to 4 hours.   The Pot Book 2010
Smoking cannabis
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• Lower temperature, low particulates and markedly less of toxic 
carbon monoxide make this much safer and cleaner than smoking
• There is markedly better THC delivery to blood compared to 
smoking - 30% of THC content is lost to pyrolysis (combustion)in 
smoking.
Vaporization
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“Hash Oil” 
• Ambrosia hybrid iso/ethyl extract contains 48 mg/mL THC + 8 mg 
CBD. Thinned in MCT to 12-24 mg THC/mL . 
• Regular strength morning dose for pain, spasm, anxiety, depression, 
PTSD, etc.  0.15 mL which  delivers 0.3 mg CBD, 1.8 mg THC.  
• A larger dose later in the day may be 0.25 mL, yielding 0.5 mg CBD 
and 3 mg THC.  Like smoking hash.
• “High Test” dose: 0.40 mL = 0.8 mg CBD & 4.8 mg THC
• At 24% an Extra Strength HT 0.4 mL cap = 9.6 mg THC
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• http://www.cbc-canada.ca/recipes/cbcoc-official-recipe-book
• www.hempology.ca Ted Smith
• Cannoil:  43 gm bud, 1 litre olive oil, strain, add 11 Tbsp. 
lecithin
• Green butter: 2 oz. leaf, 1 lb butter, strain, add 5 Tbsp. lecithin
• Buddha oil: 4 2/3 oz leaf, 1 litre olive or grapeseed oil, strain, 
add 11 Tbsp. lecithin
Edibles
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• Kettle of water – bring to a boil and add
• 1 pound butter.  
• 1 ounce good bud
• Boil 2 hours, making sure temp doesn’t exceed 212° F  - don’t let 
the pot boil dry. 
• Strain out plant material, add water, re-boil.
• Mix both batches, let cool.  The butter will congeal on top. 
• Store butter covered, in fridge. 
Cannabutter
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 Decarboxylate herb 15 minutes in oven at 250° (or 1 hour at 150°). 
 One ounce of bud, leaf or ”shake” per cup of oil
 Put in crock pot on LOW setting for 20+ minutes
 Strain through cheesecloth
 Coconut or grapeseed oil as also used.
Olive Oil Infusion
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Buddha Balls are carefully designed to be easy on compromised 
digestive systems such as those with Crohn’s disease and diabetics, 
and are a complete meal replacement. They contain 
oats, hemp protein, hemp hearts, soy protein,
whey protein, coconut, sunflower
seeds, almond powder, honey, 
and  cannabis infused olive oil.
Buddha Balls for Cachexia




1 cup raw unsalted sunflower seeds
1 1⁄2 cups whey protein
1 1⁄2 cups soy protein
1⁄2 cup hemp protein
1⁄2 cup hemp hearts
Mix......
1 cup Buddha Ball Oil  (Cannabis infused olive oil)
Mix......
400g honey (2 1⁄2 ladles)
Mix thoroughly.....
Put 1 cup almond powder in a small bowl
Form the balls and use almonds to coat the outside
Add 1⁄2 cup chocolate chips for 1⁄2 the batch
........Makes 24
Buddha Balls Recipe
Third Annual Palliative Care Institute Conference
Olive or coconut oil extracts are effective for many skin disorders, 
and can be rubbed into sore joints.   4 2/3 oz leaf, 1 liter oil, ½ 
bottle vitamin E oil
Rick Simpson dilutes the phoenix tears type oil in 5 parts 99% 
iso-propyl alcohol for topical use, and claims this “most medicinal 
plant in the world” cured his skin cancer.  
Topical Cannabis Oil
Third Annual Palliative Care Institute Conference
• Grind decarboxylated bud 15’@ 250° to flour consistency
• Melt cocoa butter and/or beeswax in a double-boiler 
Coconut oil can also be used.
• Mix equal parts cannabis flour, or 1 – 2 gm RSO hemp 
oil, per 100 gm cocoa butter.
• Add up to 4% beeswax for shape and healing.
• Pour into moulds or shape 
into cylinders on wax paper.
• Refrigerate/freeze until needed.
Cannabis Suppositories
Third Annual Palliative Care Institute Conference
Active against cholangiocarcinoma, glioblastoma, 
carcinoid, breast, lung, prostate, pancreatic, 
leukemia – in vitro and in pre-clinical animal studies
via ceramide, akt/mTOR, MMP, PPARɣ, autophagy, 
EGFR, apoptosis, etc.……..
Abrams, Weil, Guzman 2009              
Singh & Bali 2013 – a case report
Cannabis as a Cancer Treatment?
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• Rick Simpson used one pound of high THC 
Indicas .
• 8 litres of toxic and dangerous naptha or 
butane solvents.
• Short contact of herb with solvent  
www.phoenixtears.ca
• Yield – about 60 grams of thick, greasy oil.
• Consume 60 + grams RSO in 90 days
“Rick Simpson Hemp Oil”
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• Ideal is 1:1 mix of ethyl and isopropyl alcohols.
• Iso yields ~ 25 gm oil / lb > than pure ethanol.
• 15 minute ice-cold maceration maximizes 
bio-actives and GI tolerability of the oil.
• Using high CBD:THC hybrids: Cannatonic - 6%/6%        Romano 2013
•
Phoenix Tears Oil Today 
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• Warm the syringe in hot water. 
• Dose 4 to 72 insulin units, up to 1 gm/day.       
• Start at bedtime, as needed add doses at breakfast, lunch and 5 
pm.  
• Use citicoline to prevent excess intoxication, or lemonade, pine 
nuts.
• Ψ A/Es – avoid alcohol & sedatives!
Taking “RSO” hemp oil 
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Grain of Rice – RSO Starting Dose
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1 gram oil = 0.71 mL = “00” capsule = ¼ tsp
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Anecdotes and Legends
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Brain tumour cured by cannabis ?
No chemotherapy, no diet change –
just RSO





Documentation of healthcare professional’s authorization to engage 
in the Medical Use of Cannabis in the State of Washington 
Authorization for:  Patient name here DOB:  ____________ 
Designation of insert another close person who is authorized to pick 
up medicine at dispensary as PRIMARY CAREGIVER under Wash. Rev. 
Code §§69.51A.010, 69.51A.040 (2007). 
I, your name, am a licensed naturopathic physician in the State of Washington 
under Washington statute 18.36A, and I have diagnosed the above individual as 
having a debilitating condition as defined in RCW 69.51A.010(6). 
I have advised the above named individual about the potential risks and 
benefits of the medical use of cannabis.  I have a long medical relationship with 
this person and am familiar with the extent and nature of their disease state; in 
my medical opinion they will likely benefit from medical cannabis. 
Your name and credentials .   WA License ___________ 
________________________________       Signed on  ________ 
This recommendation expires on _________ 
Documentation of risk/benefit is in the medical record. 
CBD rich concentrated extract: A 30-day supply as stipulated in WA 
RCW 69.51A.010(6) for this person is 60 mL Tincture, two ounces dry 
marijuana or 60 mL Oil Infusion / extract, 1 Gram Co2-Raw Oil-CBD Rich 
or 60 mL.  Refill PRN.  
Print on tamper proof Rx paper
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• Integrative Oncology by Donald Abrams and Andrew Weil, 2nd ed.
• The Pot Book, A Complete Guide to Cannabis – It’s Role in Medicine, 
Politics, Science and Culture, Julie Holland, ed., 2010, Park Street Press.
• Hempology 101- The History and Uses of Cannabis Sativa, 4th edition, Ted 
Smith, 2012, The International Hempology 101 Society. 
• Marijuana – Gateway to Health – How Cannabis Protects Us from Cancer 
and Alzheimer’s Disease, Clint Werner, 2011, Dachstar Press. 
• Cannabis – A History, Martin Booth, 2003,Picador – St. Martin’s Press.
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1. Cannabis is useful therapy for some patients.  Don’t be afraid to 
recommend to your patients. Ask about prior use.
2. Visit your local cannabis dispensary and ask for a tour.
3. Start small dose orally.  5 mg CBD and 1 mg THC.  Take before bed.  
Increase dose until JND in mood, pain, appetite.  
4. Wide therapeutic dose range.
5. Refer your pt to a trusted medical dispensary near you.
6. Tell the dispensary to provide a low dose capsule or high dose oil in a 1 ml 
syringe.  Call the dispensary and consult with them.  
7. Certified organic cannabis may be hard to obtain.  So teach pts how to 
grow make their own at home.  
Take home 
Third Annual Palliative Care Institute Conference
End of presentation
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Will western palliative and hospice 
medicine be using psychedelic drugs 
to improve QOL and the death and 
dying experience?
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 Some Central America indigenous groups use psilocybe mushrooms as a 
sacrament.
 Some Southwest American indigenous groups use peyote as a sacrament.
 78% of Amazonian basic tribal indigenous groups use ayahuasca as a 
sacramental tea
 Used in tribal groups as a community and family medicine.
 Most psychedelic natural and synthetic products are powerful 5-HT1a 
receptor agonists.
 Santo Daime Church and Uñiao do Vegetal Church use ayahuasca as a 
sacramental tea
Is there a role for psychedelic medicines 
in modern western end-of-life care?
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• LSD used by psychiatrists in 1960’s and 70’s dose 1 mcg/kg = 
0.001 mg/kg for treating anxiety, depression, drug and alcohol 
dependence and OCD.
• Became FDA schedule I in 1970 and LSD research stopped and 
use went underground
• Psilocybin reduced fear of death in psilocybin trial at UCLA (Grob 
et al 2010) 0.2 mg/kg dose 
• Psilocybin human studies at Johns Hopkins and NYU in normal 
adults
• MDMA trial starting soon for PTSD.
Psychedelic medicine clinical trials 
and practice
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Psilocybin can occasion mystical-type experiences having substantial and 
sustained personal meaning and spiritual significance.
Griffiths RR, Richards WA, McCann U, Jesse R.
Psychopharmacology (Berl). 2006 Aug;187(3)
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B. caapi vine/stem
Third Annual Palliative Care Institute Conference
Psychotria viridis leaves and flowers
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P. Viridis in cultivation in Peru
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Towards an FDA, IRB and DEA 
approval clinical trial of ayahuasca for 
the treatment of moderate recurrent 
depression in adults
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Fig. 2.   Decreased CBF after  psilocybin (ASL perfusion  fMRI). Regions where there was 
significantly decreased CBF after  psilocybin versus after  placebo are shown in blue (z: 2.3–
3.7). Mixed effects analysis, z > 2.3, P < 0.05 whole-brain cluster-corrected, n = 15. LH, left 
hemisphere; RH, right  hemisphere. Note, we observed no increases in CBF in any region.
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Fig. 4. Brain deactivations after psilocybin. (Upper) Regions where there was a significant 
decrease in the BOLD signal after psilocybin versus after placebo (z: 1.8–3). Mixed-effects 
analysis, z > 1.8, P < 0.05 whole brain cluster corrected, n = 15. (Lower) Regions where there 
was a consistent decrease inCBF and BOLD after psilocybin. For display purposes, significant 
BOLD decreases were calculated within a mask based on the ASL result (Fig. 2) atan 
uncorrected voxel level threshold of P = 0.05. Note, we observed noincreases in CBF or BOLD 
signal in any region.
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The human heart generates the largest 
electromagnetic field. 
We really are interconnected.
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